Goldman Sachs
LUCD icon

Goldman Sachs’s Lucid Diagnostics LUCD Stock Holding History

Goldman Sachs’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.6K Sell
70,611
-172,047
-71% -$185K ﹤0.01% 6369
2026
Q1 		$279K Sell
242,658
-46,617
-16% -$59.3K ﹤0.01% 5931
2025
Q4 		$315K Sell
289,275
-270,879
-48% -$303K ﹤0.01% 5839
2025
Q3 		$566K Buy
560,154
+251,476
+81% +$275K ﹤0.01% 5433
2025
Q2 		$355K Buy
308,678
+222,376
+258% +$287K ﹤0.01% 5354
2025
Q1 		$129K Buy
86,302
+22,727
+36% +$27.3K ﹤0.01% 5735
2024
Q4 		$52K Buy
+63,575
New +$56.1K ﹤0.01% 5842
2022
Q1 		– Sell
-24,540
Closed -$132K – 6759
2021
Q4 		$132K Buy
+24,540
New +$199K ﹤0.01% 6047

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Goldman Sachs's LUCD Position: Q2 2026 in Review

Goldman Sachs reduced its Lucid Diagnostics (LUCD) stake by 71% in Q2 2026, selling an estimated $185K and leaving 70,611 shares worth $75.6K. The position accounts for ﹤0.01% of the portfolio, ranked #6369.

Goldman Sachs first reported a position in LUCD in Q4 2021 and has held it in 8 quarters since. The position peaked at $566K in Q3 2025. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Goldman Sachs held 70,611 shares of Lucid Diagnostics worth $75.6K as of Q2 2026.
  • Goldman Sachs sold 172,047 Lucid Diagnostics shares in Q2 2026, an estimated $185K.
  • Lucid Diagnostics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6369 holding.
  • Goldman Sachs first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 8 quarters since.
  • Goldman Sachs's Lucid Diagnostics position peaked at $566K in Q3 2025.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.